Mobilitätsverlust reduziert Produktivität und Einkommen von Menschen mit multipler SkleroseBusiness Wire, 28.07.2010
Neuen Forschungsergebnissen zufolge führt die Mobilitätsbehinderung von
Menschen mit multipler Sklerose (MS) zu erheblichen Auswirkungen auf die
Produktivität am Arbeitsplatz sowie auf das Einkommen der Betroffenen.
Fast drei Viertel (72 %) der Befragten gaben an, dass ihre
Mobilitätsprobleme ihr Arbeitsleben stark beeinträchtigten, und fast
zwei Drittel (64 %) mussten aufgrund ihrer mit MS verbundenen
Mobilitätsprobleme Einkommensverluste hinnehmen.1
more
Unabhängiges Aufsichtskomitee lobt Alcon für das Übertreffen der erwarteten Ergebnisse für das zweite QuartalBusiness Wire, 27.07.2010
Das unabhängige Aufsichtskomitee von Alcon (das "Komitee") hat heute
festgehalten, dass Alcon auch im zweiten Quartal 2010 erneut starke
Ergebnisse erzielt hat. Der bereinigte Gewinn je Aktie von Alcon in Höhe
von USD 2,22 für Q2 2010 bedeutete eine Wachstumsrate von 14,4 % im
Jahresvergleich und übertraf die durchschnittliche Konsensschätzung der
Wall Street von USD 2,03 je Aktie um 9,4 %. Die starke Zunahme beim
Gewinn je Aktie von Alcon wurde von einer 11,3-prozentigen Steigerung
beim organischen Umsatz angetrieben, die sich teilweise aus einer
22,3-prozentigen Steigerung beim Umsatz von spitzentechnologischen
Intraokularlinsen, einer 17,2-prozentigen Steigerung beim Glaukom-Umsatz
und einer 24,2-prozentigen Steigerung beim Umsatz in Schwellenmärkten
ergab.
more
Results from Two Multi-Site Collaborative Studies Highlight the Value of 454 Sequencing Systems for Genotyping ApplicationsBusiness Wire, 27.07.2010
454 Life Sciences, a Roche Company (SWX:RO)(SWX:ROG)(Pink Sheets:
RHHBY), has announced promising new results from a multi-site
collaborative research study which used the company's Genome Sequencer
FLX System to perform HIV drug-resistant mutation detection. The
findings were outlined last month at the International HIV & Hepatitis
Virus Drug Resistance Workshop in Dubrovnik, Croatia, and follow only
weeks after the results from a similar multi-site research study, which
used the company's sequencing technology for high-resolution HLA
genotyping, were presented at the European Immunogenetics and
Histocompatibility Conference in Florence, Italy.
more
Alcon Independent Director Committee Commends Alcon on Stronger Than Expected Q2 EarningsBusiness Wire, 26.07.2010
The Alcon Independent Director Committee (the "Committee") noted today
that Alcon once again delivered strong earnings in the second quarter of
2010. Alcon's 2Q 2010 Adjusted EPS of $2.22 per share represented a
year-over-year growth rate of 14.4% and exceeded Wall Street's mean
consensus estimate of $2.03 per share by 9.4%. Alcon's strong EPS growth
was driven by an 11.3% increase in organic sales resulting, in part,
from a 22.3% increase in advanced technology intraocular lens sales, a
17.2% increase in glaucoma sales and a 24.2% increase in emerging market
sales.
more
Alcon Posts 12.5 Percent Rise in Second Quarter SalesBusiness Wire, 26.07.2010
Alcon, Inc. (NYSE:ACL) reported that global sales rose 12.5 percent to
$1.89 billion for the second quarter of 2010, or 11.3 percent excluding
the impact of foreign exchange fluctuations and acquisitions. Revenue
from acquisitions added 40 basis points to sales growth in the quarter,
while foreign currency fluctuations added 80 basis points of growth.
more
NovImmune unterschreibt exklusiven Antikörper-Lizenzierungsvertrag mit GenentechBusiness Wire, 26.07.2010
NovImmune, ein Biotech-Unternehmen, das therapeutische monoklonale
Antikörper entwickelt, gab heute bekannt, dass ein exklusiver
Lizenzierungsvertrag für einen menschlichen monoklonalen Antikörper
gegen Interleukin-17 (IL-17) inklusive Back-up-Molekülen mit Genentech,
einem Mitglied der Roche Gruppe (SIX: RO, ROG; OTCQX: RHHBY),
unterschrieben worden ist. In letzter Zeit hat die
Signalisierungskaskade von IL-17 grosses Interesse in der akademischen
Forschung und Industrie hervorgerufen, weil sie ein möglicher
Ansatzpunkt für die Behandlung von wichtigen und häufigen Krankheiten
bietet.
more
NovImmune Enters Exclusive Antibody Licensing Agreement with GenentechBusiness Wire, 26.07.2010
NovImmune, an antibody-focused research and development biotech
company, announced today that it successfully entered into an exclusive
licensing agreement with Genentech Inc. a member of the Roche
Group (SIX: RO, ROG; OTCQX: RHHBY) for a proprietary anti-IL-17 fully
human monoclonal antibody, and access to back-up antibodies. Recently,
the IL-17 signaling pathway has received significant academic and
corporate interest as its manipulation may potentially provide new
treatment opportunities for major medical conditions.
more
European Medical Device Reimbursement Reports Updated and Expanded for EU / European MarketsBusiness Wire, 20.07.2010
Factory Reimbursement announced a complete update of its popular
catalog of country-specific medical device Reimbursement Reports.
Additionally, the Reimbursement Reports are now available for two new
markets: The Netherlands and Belgium. Formerly known as the
Jacoti Reports, the ready-to-download reports offer the most
comprehensive information available about today's medical device
reimbursement regulations in seven European Union countries. All
are available for purchase online at www.factory-reimbursement.com.
more
Roche and Exiqon Agree on Joint Marketing Approach for their RT PCR Assay SystemsBusiness Wire, 20.07.2010
Roche (SIX:
RO, ROG; OTCQX: RHHBY) and Exiqon (NASDAQ OMX: EXQ) join marketing
forces for Roche
Applied Science´s RealTime ready assays and Exiqon`s miRCURY LNA?
Universal RT microRNA qPCR system. As indicated by respective links on
their websites, each system will complement the cooperator ´s product
portfolio. A bundle of measures like webinars and seminars and linked
internet appearances are planned to promote the joint offer. Financial
terms of the agreement were not disclosed.
more
HOYA Announces Strategic Investment in Adoptics for the Development of a Shape-changing Intraocular Lens that Mimics the Natural Accommodation Process of the EyeBusiness Wire, 20.07.2010
HOYA announced today that the Company has formed a strategic partnership
with Adoptics (Switzerland) through an investment that will fund the
development of a shape-changing accommodating intraocular lens (AIOL).
more
Pantec Biosolutions Closes CHF 20 Million FinancingBusiness Wire, 20.07.2010
Pantec Biosolutions AG, a privately-owned company developing innovative
technologies for transdermal drug delivery, today announced the closing
of a CHF 20 million investment achieved by two financing rounds. The
StemCell Holding AG, an Austrian investment company in the life sciences
sector, acted as lead investor. No further terms were disclosed.
more